Revolutionizing Drug Delivery with Gattefosse Innovative Lipid-Based Excipients – Interview

Discover the interview given by Alexandre Gil, Gattefossé Group Director for Pharmaceuticals, in Pharma Industrial India. In this interview, he discussed the advantages of Gattefossé excipients, the personalized medicine trend, the current Gattefossé  R&D focus areas and their ambition for the Indian market.

First part of the interview:

Q: What differentiates Gattefossé’s pharmaceutical excipients from those of its competitors in the global market?

At Gattefossé, we provide lipid-based excipients that have the particularity of being versatile, meaning that they can be used for a variety of administration routes (oral, topical, rectal, vaginal), a variety of dosage forms and for different markets (human health, animal health and nutraceuticals). Moreover, our excipients are highly functional: they bring valuable assets to formulations, for example via boosting an API bioavailability or modifying its release. Our application laboratories regularly conduct studies to showcase their abilities and are consistently working on new applications for our excipients. Finally, it is important to mention our commitment to responsible sourcing of our excipients. As the main raw material for our excipients’ production is palm oil, we are aware of its link with deforestation. Therefore, we have been, for several years now, an active member of the RSPO (Roundtable on Sustainable Palm Oil) to ensure a responsible supply of palm oil, in line with our CSR strategy.

Q: How is Gattefossé addressing the trend of personalized medicine in its pharmaceutical offerings?

Personalized medicine is a major aspect of the future of innovation in healthcare. When tailoring a treatment to an individual, it is also necessary to find a formulation and a formulation technology that can easily be tailored to different APIs in different doses. Recently, we have been working on how to use our excipients in 3D printing, because 3D printing technology allows for precise control on drug dosage and is ideal for on-demand production. We demonstrated that our surfactants, Gelucire® 44/14 and Gelucire® 48/16 could successfully be used to design 3D-printed tablet exhibiting enhanced drug delivery performance. We believe in this technology and continue to work on it, as lipid-based excipients have clear advantages: their low melting temperatures (30–75 °C) and rapid recrystallization make them easy to process during printing.

Read the complete  interview here

Source: Revolutionizing Drug Delivery with Gattefosse Innovative Lipid-Based Excipients, Pharmaindustrial India, Gattefossé, 2024-12-26, website Revolutionizing Drug Delivery with Gattefosse Innovative Lipid-Based Excipients – Interviews

If you have any questions or need a sample by Gattefossé, please feel free to contact us: